A new preparation of modified immune serum globulin (human) suitable for intravenous administration. II. Functional characterization.
The commercial immune serum globulin (ISG) product is suitable for use in passive immunization only by intramuscular administration; intravenous use results in vasomotor side reactions. We report the functional characterization of a chemically modified ISG (MISG) that is essentially free of nonspecific complement-binding activity and contains no new antigenic determinants. The half-life values for MISG given intravenously to rabbits, guinea pigs, and humans are shown not to be different from that of ISG. The MISG we describe is shown to fulfill the in vitro and in vivo criteria of stability, safety, function, and half-life, making it suitable for human intravenous administration.
D000818:Animals; D003165:Complement System Proteins / Q000276:immunology; D000939:Epitopes; D006168:Guinea Pigs; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D011817:Rabbits; D014666:Vasomotor System / Q000187:drug effects
D000939:Epitopes; D007106:Immune Sera; D003165:Complement System Proteins